Inflammatory bowel disease (IBD) is a complex chronic inflammatory disorder of the gastrointestinal tract. Extracellular adenosine triphosphate (eATP) produced by the commensal microbiota and host cells activates purinergic signaling, promoting intestinal inflammation and pathology. Based on the role of eATP in intestinal inflammation, we developed yeast-based engineered probiotics that express a human P2Y2 purinergic receptor with up to a 1,000-fold increase in eATP sensitivity. We linked the activation of this engineered P2Y2 receptor to the secretion of the ATP-degrading enzyme apyrase, thus creating engineered yeast probiotics capable of sensing a pro-inflammatory molecule and generating a proportional self-regulated response aimed at its neutralization. These self-tunable yeast probiotics suppressed intestinal inflammation in mouse models of IBD, reducing intestinal fibrosis and dysbiosis with an efficacy similar to or higher than that of standard-of-care therapies usually associated with notable adverse events. By combining directed evolution and synthetic gene circuits, we developed a unique self-modulatory platform for the treatment of IBD and potentially other inflammation-driven pathologies.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Huang, H. et al. Fine-mapping inflammatory bowel disease loci to single-variant resolution. Nature 547, 173–178 (2017).
Neurath, M. F. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat. Immunol. 20, 970–979 (2019).
Blander, J. M., Longman, R. S., Iliev, I. D., Sonnenberg, G. F. & Artis, D. Regulation of inflammation by microbiota interactions with the host. Nat. Immunol. 18, 851–860 (2017).
Jostins, L. et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).
Lloyd-Price, J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569, 655–662 (2019).
Plichta, D. R., Graham, D. B., Subramanian, S. & Xavier, R. J. Therapeutic opportunities in inflammatory bowel disease: mechanistic dissection of host–microbiome relationships. Cell 178, 1041–1056 (2019).
Suez, J., Zmora, N., Segal, E. & Elinav, E. The pros, cons, and many unknowns of probiotics. Nat. Med. 25, 716–729 (2019).
Aggarwal, N., Breedon, A. M. E., Davis, C. M., Hwang, I. Y. & Chang, M. W. Engineering probiotics for therapeutic applications: recent examples and translational outlook. Curr. Opin. Biotechnol. 65, 171–179 (2020).
Hwang, I. Y. et al. Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models. Nat. Commun. 8, 15028 (2017).
McKay, R. et al. A platform of genetically engineered bacteria as vehicles for localized delivery of therapeutics: toward applications for Crohn’s disease. Bioeng. Transl. Med. 3, 209–221 (2018).
Idzko, M., Ferrari, D. & Eltzschig, H. K. Nucleotide signalling during inflammation. Nature 509, 310–317 (2014).
Atarashi, K. et al. ATP drives lamina propria TH17 cell differentiation. Nature 455, 808–812 (2008).
Gulbransen, B. D. et al. Activation of neuronal P2X7 receptor–pannexin-1 mediates death of enteric neurons during colitis. Nat. Med. 18, 600–604 (2012).
Takenaka, M. C., Robson, S. & Quintana, F. J. Regulation of the T cell response by CD39. Trends Immunol. 37, 427–439 (2016).
Mascanfroni, I. D. et al. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat. Immunol. 14, 1054–1063 (2013).
Takenaka, M. C. et al. Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat. Neurosci. 22, 729–740 (2019).
Cekic, C. & Linden, J. Purinergic regulation of the immune system. Nat. Rev. Immunol. 16, 177–192 (2016).
Vuerich, M., Robson, S. C. & Longhi, M. S. Ectonucleotidases in intestinal and hepatic inflammation. Front. Immunol. 10, 507 (2019).
Sen, S. & Mansell, T. J. Yeasts as probiotics: mechanisms, outcomes, and future potential. Fungal Genet. Biol. 137, 103333 (2020).
Brown, A. J. et al. Functional coupling of mammalian receptors to the yeast mating pathway using novel yeast/mammalian G protein α-subunit chimeras. Yeast 16, 11–22 (2000).
Shaw, W. M. et al. Engineering a model cell for rational tuning of GPCR signaling. Cell 177, 782–796 (2019).
Lazarowski, E. R. & Harden, T. K. Quantitation of extracellular UTP using a sensitive enzymatic assay. Br. J. Pharmacol. 127, 1272–1278 (1999).
Wan, P. et al. Extracellular ATP mediates inflammatory responses in colitis via P2 × 7 receptor signaling. Sci. Rep. 6, 19108 (2016).
Di Virgilio, F., Pinton, P. & Falzoni, S. Assessing extracellular ATP as danger signal in vivo: the pmeLuc system. Methods Mol. Biol. 1417, 115–129 (2016).
Hillmann, P. et al. Key determinants of nucleotide-activated G protein-coupled P2Y2 receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. J. Med. Chem. 52, 2762–2775 (2009).
Schutz, M. et al. Directed evolution of G protein-coupled receptors in yeast for higher functional production in eukaryotic expression hosts. Sci. Rep. 6, 21508 (2016).
Montaner, S., Kufareva, I., Abagyan, R. & Gutkind, J. S. Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases. Annu. Rev. Pharmacol. Toxicol. 53, 331–354 (2013).
Venkatakrishnan, A. J. et al. Diverse activation pathways in class A GPCRs converge near the G-protein-coupling region. Nature 536, 484–487 (2016).
Komoszynski, M. A. Comparative studies on animal and plant apyrases (ATP diphosphohydrolase EC 220.127.116.11) with application of immunological techniques and various ATPase inhibitors. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 113, 581–591 (1996).
Nourizad, N., Ehn, M., Gharizadeh, B., Hober, S. & Nyren, P. Methylotrophic yeast Pichia pastoris as a host for production of ATP-diphosphohydrolase (apyrase) from potato tubers (Solanum tuberosum). Protein Expr. Purif. 27, 229–237 (2003).
Derkx, B. et al. Tumour-necrosis-factor antibody treatment in Crohn’s disease. Lancet 342, 173–174 (1993).
Dotan, I. et al. The role of integrins in the pathogenesis of inflammatory bowel disease: approved and investigational anti-integrin therapies. Med. Res. Rev. 40, 245–262 (2020).
Shen, C. et al. Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization? Inflamm. Bowel Dis. 13, 308–316 (2007).
Goettel, J. A. et al. AHR activation is protective against colitis driven by T cells in humanized mice. Cell Rep. 17, 1318–1329 (2016).
Nowarski, R., Jackson, R. & Flavell, R. A. The stromal intervention: regulation of immunity and inflammation at the epithelial–mesenchymal barrier. Cell 168, 362–375 (2017).
Sonnenberg, G. F., Fouser, L. A. & Artis, D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 12, 383–390 (2011).
Trivedi, P. P. & Jena, G. B. Dextran sulfate sodium-induced ulcerative colitis leads to increased hematopoiesis and induces both local as well as systemic genotoxicity in mice. Mutat. Res. 744, 172–183 (2012).
Musch, M. W. et al. T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+/K+-ATPase. J. Clin. Invest. 110, 1739–1747 (2002).
Ueno, N. et al. TU-100 (Daikenchuto) and ginger ameliorate anti-CD3 antibody induced T cell-mediated murine enteritis: microbe-independent effects involving Akt and NF-κB suppression. PLoS ONE 9, e97456 (2014).
Goretsky, T. et al. p53 mediates TNF-induced epithelial cell apoptosis in IBD. Am. J. Pathol. 181, 1306–1315 (2012).
He, Q. et al. Dysbiosis of the fecal microbiota in the TNBS-induced Crohn’s disease mouse model. Appl. Microbiol. Biotechnol. 100, 4485–4494 (2016).
Frank, D. N. et al. Molecular–phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl Acad. Sci. USA 104, 13780–13785 (2007).
Machiels, K. et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63, 1275–1283 (2014).
Chen, Y. et al. Genetic circuit design automation for yeast. Nat. Microbiol. 5, 1349–1360 (2020).
Braat, H. et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin. Gastroenterol. Hepatol. 4, 754–759 (2006).
Nash, A. K. et al. The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome 5, 153 (2017).
Sokol, H. et al. Fungal microbiota dysbiosis in IBD. Gut 66, 1039–1048 (2017).
Enaud, R. et al. The mycobiome: a neglected component in the microbiota–gut–brain axis. Microorganisms 6, 22 (2018).
Martins, F. S. et al. Oral treatment with Saccharomyces cerevisiae strain UFMG 905 modulates immune responses and interferes with signal pathways involved in the activation of inflammation in a murine model of typhoid fever. Int. J. Med. Microbiol. 301, 359–364 (2011).
Rizzetto, L. et al. Fungal chitin induces trained immunity in human monocytes during cross-talk of the host with Saccharomyces cerevisiae. J. Biol. Chem. 291, 7961–7972 (2016).
Zanello, G. et al. Saccharomyces cerevisiae modulates immune gene expressions and inhibits ETEC-mediated ERK1/2 and p38 signaling pathways in intestinal epithelial cells. PLoS ONE 6, e18573 (2011).
Chiaro, T. R. et al. A member of the gut mycobiota modulates host purine metabolism exacerbating colitis in mice. Sci. Transl. Med. 9, eaaf9044 (2017).
Rinaldi, M., Perricone, R., Blank, M., Perricone, C. & Shoenfeld, Y. Anti-Saccharomyces cerevisiae autoantibodies in autoimmune diseases: from bread baking to autoimmunity. Clin. Rev. Allergy Immunol. 45, 152–161 (2013).
Tiago, F. C. et al. Effect of Saccharomyces cerevisiae strain UFMG A-905 in experimental model of inflammatory bowel disease. Benef. Microbes 6, 807–815 (2015).
Hudson, L. E. et al. Functional heterologous protein expression by genetically engineered probiotic yeast Saccharomyces boulardii. PLoS ONE 9, e112660 (2014).
Durmusoglu, D. et al. In situ biomanufacturing of small molecules in the mammalian gut by probiotic Saccharomyces boulardii. ACS Synth. Biol. 10, 1039–1105 (2021).
Takemura, N. et al. Eosinophil depletion suppresses radiation-induced small intestinal fibrosis. Sci. Transl. Med. 10, eaan0333 (2018).
Wilhelm, K. et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat. Med. 16, 1434–1438 (2010).
Berer, K. et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479, 538–541 (2011).
Rothhammer, V. et al. Microglial control of astrocytes in response to microbial metabolites. Nature 557, 724–728 (2018).
Bashor, C. J., Helman, N. C., Yan, S. & Lim, W. A. Using engineered scaffold interactions to reshape MAP kinase pathway signaling dynamics. Science 319, 1539–1543 (2008).
Scott, B. M. et al. Coupling of human rhodopsin to a yeast signaling pathway enables characterization of mutations associated with retinal disease. Genetics 211, 597–615 (2019).
Rafehi, M. et al. Molecular recognition of agonists and antagonists by the nucleotide-activated G protein-coupled P2Y2 receptor. J. Med. Chem. 60, 8425–8440 (2017).
Wiederstein, M. & Sippl, M. J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 35, W407–W410 (2007).
Lovell, S. C. et al. Structure validation by Cα geometry: ϕ,ψ and Cβ deviation. Proteins 50, 437–450 (2003).
Lee, G. R. & Seok, C. Galaxy7TM: flexible GPCR–ligand docking by structure refinement. Nucleic Acids Res. 44, W502–W506 (2016).
Ballesteros, J. A. & Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure–function relations in G protein-coupled receptors. In Methods in Neurosciences 25 (ed. Stuart, C. S.), 366–428 (Academic Press, 1995).
Ryan, O. W. et al. Selection of chromosomal DNA libraries using a multiplex CRISPR system. eLife 3, e03703 (2014).
Prykhozhij, S. V., Rajan, V., Gaston, D. & Berman, J. N. CRISPR multitargeter: a web tool to find common and unique CRISPR single guide RNA targets in a set of similar sequences. PLoS ONE 10, e0119372 (2015).
Pliatsika, V. & Rigoutsos, I. ‘Off-Spotter’: very fast and exhaustive enumeration of genomic lookalikes for designing CRISPR/Cas guide RNAs. Biol. Direct 10, 4 (2015).
Knowles, A. F. The GDA1_CD39 superfamily: NTPDases with diverse functions. Purinergic Signal. 7, 21–45 (2011).
Cox, L. M. et al. Calorie restriction slows age-related microbiota changes in an Alzheimer’s disease model in female mice. Sci. Rep. 9, 17904 (2019).
Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335–336 (2010).
Yoon, S. H. et al. Introducing EzBioCloud: a taxonomically united database of 16S rRNA gene sequences and whole-genome assemblies. Int. J. Syst. Evol. Microbiol. 67, 1613–1617 (2017).
Lozupone, C., Lladser, M. E., Knights, D., Stombaugh, J. & Knight, R. UniFrac: an effective distance metric for microbial community comparison. ISME J. 5, 169–172 (2011).
Segata, N. et al. Metagenomic biomarker discovery and explanation. Genome Biol. 12, R60 (2011).
Erben, U. et al. A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int. J. Clin. Exp. Pathol. 7, 4557–4576 (2014).
Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675 (2012).
Babicki, S. et al. Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res. 44, W147–W153 (2016).
Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90–W97 (2016).
This work was supported by grants NS102807, ES02530, ES029136 and AI126880 from the NIH; RG4111A1 from the National MS Society; PA-1604-08459 from the International Progressive MS Alliance; and NSERC 492911 from the Natural Sciences Engineering Research Council of Canada. B.M.S. was supported by an Ontario Graduate Scholarship and by the Professional Research Experience Program agreement between the National Institute of Standards and Technology (NIST) and the University of Maryland. C.G.-V. was supported by an Alfonso Martín Escudero Foundation postdoctoral fellowship and by postdoctoral fellowship ALTF 610-2017 from the European Molecular Biology Organization. J.P. was supported by grant 2019/04780-7 from the São Paulo Research Foundation (FAPESP). This paper is dedicated to the memory of Dan S. Tawfik. We thank Z. Kelman and J. Marino of the University of Maryland Institute for Bioscience and Biotechnology Research for use of their incubators and W. Shaw of Imperial College London for providing yeast codon-optimized sfGFP. We thank the Harvard Medical School Rodent Histopathology Core, which provided histopathology service. We thank the NeuroTechnology Studio at Brigham and Women’s Hospital for providing access to the Leica DMi8 fluorescent microscope and consultation on data acquisition and data analysis. B.M.S. is an International Associate of the NIST. The NIST notes that certain commercial equipment, instruments and materials are identified in this paper to describe an experimental procedure as completely as possible. In no case does this identification imply a recommendation or endorsement by the NIST, nor does it imply that the materials, instruments or equipment are necessarily the best available for the purpose. The opinions expressed in this article are the authors’ own and do not necessarily represent the views of the NIST.
B.M.S., C.G.-V., B.S.W.C., S.G.P. and F.J.Q. filed a patent for the use of engineered yeast to treat inflammation. All other authors declare no competing interests.
Peer review information Nature Medicine thanks Cathryn Nagler and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Saheli Sadanand was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
a,b, Yeasts from the BS016 strain transformed with plasmid pRS316 pTDH3 P2Y2 (WT human P2Y2 receptor) were incubated with 100 μM ATP in 300 μL (a) or 5 mL SC-URA media (b); and mCherry fluorescence was quantified. Data points represent the mean of 2 colonies. c, Engineered mating pathway response to UTP using the wild-type (WT) human P2Y2 receptor and various yeast strains with integrated Gpa1-Gα chimeras as follows: BS019 (G14), BS020 (Gq), BS016 (Gi3). Following incubation for 6h with the indicated UTP concentration, the activation of the mating pathway was monitored by quantifying mCherry fluorescence by flow cytometry. Data points represent the mean of 2 colonies.
During each FACS sort the top ~1% of mCherry fluorescence was collected. ‘Recovered’ refers to the number of yeast colonies obtained after plating sorted cells on selective media.
a, Sequence Alignment of Apyrase Genes. Human ENTPD1 (CD39), potato apyrase (RROP1) and wheat apyrase (TUAP1) were aligned using MUSCLE, in the MEGA6 alignment explorer. b, Measurement of a known ATP concentration in the presence of 5 μL yeast supernatant from strain CB008 (blue) or reaction buffer only (red). Yeast supernatant did not affect the measurement readout. n = 3 samples, error bars represent SD. c, To estimate the amount of active apyrase secreted by yeast, 50 μM ATP was incubated with the indicated concentration of commercial apyrase for 30 minutes at 30oC, with 5 μL supernatant from a culture of strain Ctrl, in a 50 μL reaction volume and residual ATP was quantified. No apyrase activity was observed when 31.3 pM commercial apyrase was added. n = 6 samples.
a, Colony forming units per mg of stool collected 6, 24 and 48h after oral gavage to the mice with either Ctrl KG, conAP KG or indAP KG yeast strains. n = 3 Ctrl, n = 5 conAP and n = 4 indAP samples per group. b, ATP relative levels in the specified portions of the gut of naïve and TNBS induced mice. n = 4 naïve, n = 6 TNBS mice per group. c, Gating strategy to measure mCherry positive yeasts in the fecal content. d, mCherry positive yeasts (% of total GFP yeast) measured by flow cytometry in the fecal content of the specified portion of the gut after 2h from oral gavage to naïve mice with ATP inducible strain indCherry KG. ATP levels were measured in the same portions of the gut. n = 3 samples for cytometry and n = 8 for eATP levels. e, mCherry positive yeasts (% of total GFP yeast) quantified by flow cytometry in the fecal content of the specified portion of the gut from TNBS treated mice 2 hours after oral gavage with indCherry KG or WTCherry KG yeast strains. f, Changes in body weight during the course of DSS-induced colitis in mice treated with engineered yeasts starting 3 days before DSS administration. n = 4 mice Healthy control and n = 3 otherwise. Two-way ANOVA followed by Tukey’s post-hoc test, ns = not significant.
Custom multiple cloning site inserted at the XmaI and BglII sites in the pCAS plasmid, obtained from AddGene68. Image generated with CLC Sequence Viewer.
About this article
Cite this article
Scott, B.M., Gutiérrez-Vázquez, C., Sanmarco, L.M. et al. Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease. Nat Med 27, 1212–1222 (2021). https://doi.org/10.1038/s41591-021-01390-x
Nature Medicine (2021)